##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	174	174	.	+	.	ID=ID_0;Name=g.G-92T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1706;ao=12;dp=1718;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G-92T;aa_name=;hgvs_nt=NC_045512.2:g.92G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006984866123399301;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	176	176	.	+	.	ID=ID_1;Name=g.C-90T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1675;ao=43;dp=1718;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C-90T;aa_name=;hgvs_nt=NC_045512.2:g.90C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025029103608847497;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	186	186	.	+	.	ID=ID_2;Name=g.C-80T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1710;ao=10;dp=1720;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C-80T;aa_name=;hgvs_nt=NC_045512.2:g.80C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005813953488372093;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	187	187	.	+	.	ID=ID_3;Name=g.A-79T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1707;ao=13;dp=1720;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A-79T;aa_name=;hgvs_nt=NC_045512.2:g.79A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007558139534883721;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	203	203	.	+	.	ID=ID_4;Name=g.C-63T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1703;ao=11;dp=1714;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C-63T;aa_name=;hgvs_nt=NC_045512.2:g.63C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006417736289381563;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_5;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1717;dp=1717;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	313	313	.	+	.	ID=ID_6;Name=L16L;alias=L16L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1673;ao=38;dp=1711;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C48T;aa_name=p.L16L;hgvs_nt=NC_045512.2:g.48C>T;hgvs_aa=YP_009724389.1:p.Leu16Leu;hgvs_alias=YP_009724389.1:Leu16Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022209234365867914;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	337	337	.	+	.	ID=ID_7;Name=R24R;alias=R24R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1697;ao=9;dp=1706;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C72T;aa_name=p.R24R;hgvs_nt=NC_045512.2:g.72C>T;hgvs_aa=YP_009724389.1:p.Arg24Arg;hgvs_alias=YP_009724389.1:Arg24Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005275498241500586;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	398	398	.	+	.	ID=ID_8;Name=H45Y;alias=H45Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1740;ao=11;dp=1751;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C133T;aa_name=p.H45Y;hgvs_nt=NC_045512.2:g.133C>T;hgvs_aa=YP_009724389.1:p.His45Tyr;hgvs_alias=YP_009724389.1:His45Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006282124500285551;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	507	507	.	+	.	ID=ID_9;Name=G82_V86del;alias=G82_V86del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1716;ao=19;dp=1750;sample_size=5;Reference_seq=ATGGTCATGTTATGGT;Variant_seq=A;nt_name=g.245_259delGTCATGTTATGGTTG;aa_name=p.G82_V86del;hgvs_nt=NC_045512.2:g.245_259del;hgvs_aa=YP_009724389.1:p.Gly82_Val86del;hgvs_alias=YP_009724389.1:Gly82_Val86del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010857142857142857;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	529	529	.	+	.	ID=ID_10;Name=L88L;alias=L88L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1700;ao=51;dp=1752;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G264T;aa_name=p.L88L;hgvs_nt=NC_045512.2:g.264G>T;hgvs_aa=YP_009724389.1:p.Leu88Leu;hgvs_alias=YP_009724389.1:Leu88Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02910958904109589;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	554	554	.	+	.	ID=ID_11;Name=Y97H;alias=Y97H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1734;ao=18;dp=1752;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T289C;aa_name=p.Y97H;hgvs_nt=NC_045512.2:g.289T>C;hgvs_aa=YP_009724389.1:p.Tyr97His;hgvs_alias=YP_009724389.1:Tyr97His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010273972602739725;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	558	558	.	+	.	ID=ID_12;Name=G98D;alias=G98D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1737;ao=14;dp=1751;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G293A;aa_name=p.G98D;hgvs_nt=NC_045512.2:g.293G>A;hgvs_aa=YP_009724389.1:p.Gly98Asp;hgvs_alias=YP_009724389.1:Gly98Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00799543118218161;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	670	670	.	+	.	ID=ID_13;Name=S135R;alias=S135R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=0;ao=1751;dp=1753;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T405G;aa_name=p.S135R;hgvs_nt=NC_045512.2:g.405T>G;hgvs_aa=YP_009724389.1:p.Ser135Arg;hgvs_alias=YP_009724389.1:Ser135Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9988590986879635;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	685	685	.	+	.	ID=ID_14;Name=K141_F143del;alias=K141_F143del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1731;ao=25;dp=1756;sample_size=5;Reference_seq=AAAGTCATTT;Variant_seq=A;nt_name=g.421_429delAAGTCATTT;aa_name=p.K141_F143del;hgvs_nt=NC_045512.2:g.421_429del;hgvs_aa=YP_009724389.1:p.Lys141_Phe143del;hgvs_alias=YP_009724389.1:Lys141_Phe143del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014236902050113895;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	715	715	.	+	.	ID=ID_15;Name=G150G;alias=G150G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1742;ao=14;dp=1756;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C450T;aa_name=p.G150G;hgvs_nt=NC_045512.2:g.450C>T;hgvs_aa=YP_009724389.1:p.Gly150Gly;hgvs_alias=YP_009724389.1:Gly150Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007972665148063782;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	745	745	.	+	.	ID=ID_16;Name=N160N;alias=N160N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1735;ao=20;dp=1756;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C480T;aa_name=p.N160N;hgvs_nt=NC_045512.2:g.480C>T;hgvs_aa=YP_009724389.1:p.Asn160Asn;hgvs_alias=YP_009724389.1:Asn160Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011389521640091117;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	805	805	.	+	.	ID=ID_17;Name=G180G;alias=G180G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=1723;ao=33;dp=1756;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G540T;aa_name=p.G180G;hgvs_nt=NC_045512.2:g.540G>T;hgvs_aa=YP_009724389.1:p.Gly180Gly;hgvs_alias=YP_009724389.1:Gly180Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01879271070615034;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1059	1059	.	+	.	ID=ID_18;Name=T265I;alias=T85I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1738;ao=17;dp=1755;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C794T;aa_name=p.T265I;hgvs_nt=NC_045512.2:g.794C>T;hgvs_aa=YP_009724389.1:p.Thr265Ile;hgvs_alias=YP_009724389.1:Thr85Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009686609686609686;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1385	1385	.	+	.	ID=ID_19;Name=H374Y;alias=H194Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1180;ao=7;dp=1187;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1120T;aa_name=p.H374Y;hgvs_nt=NC_045512.2:g.1120C>T;hgvs_aa=YP_009724389.1:p.His374Tyr;hgvs_alias=YP_009724389.1:His194Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005897219882055603;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1616	1616	.	+	.	ID=ID_20;Name=L451F;alias=L271F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1746;ao=12;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1351T;aa_name=p.L451F;hgvs_nt=NC_045512.2:g.1351C>T;hgvs_aa=YP_009724389.1:p.Leu451Phe;hgvs_alias=YP_009724389.1:Leu271Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006825938566552901;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	1627	1627	.	+	.	ID=ID_21;Name=K456E;alias=K276E;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=15;ao=28;dp=1758;sample_size=5;Reference_seq=CCAAA;Variant_seq=TCAAG;nt_name=g.CCAAA1362_1366TCAAG;aa_name=p.K456E;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Lys456Glu;hgvs_alias=YP_009724389.1:Lys276Glu;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015927189988623434;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1627	1627	.	+	.	ID=ID_22;Name=L454L;alias=L274L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=15;ao=1715;dp=1758;sample_size=5;Reference_seq=CCAAA;Variant_seq=TCAAA;nt_name=g.C1362T;aa_name=p.L454L;hgvs_nt=NC_045512.2:g.1362C>T;hgvs_aa=YP_009724389.1:p.Leu454Leu;hgvs_alias=YP_009724389.1:Leu274Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9755403868031854;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1937	1937	.	+	.	ID=ID_23;Name=S558P;alias=S378P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T1672C;aa_name=p.S558P;hgvs_nt=NC_045512.2:g.1672T>C;hgvs_aa=YP_009724389.1:p.Ser558Pro;hgvs_alias=YP_009724389.1:Ser378Pro;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2358	2358	.	+	.	ID=ID_24;Name=A698V;alias=A518V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1729;ao=25;dp=1754;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2093T;aa_name=p.A698V;hgvs_nt=NC_045512.2:g.2093C>T;hgvs_aa=YP_009724389.1:p.Ala698Val;hgvs_alias=YP_009724389.1:Ala518Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014253135689851768;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2434	2434	.	+	.	ID=ID_25;Name=S723S;alias=S543S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1684;ao=71;dp=1755;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2169T;aa_name=p.S723S;hgvs_nt=NC_045512.2:g.2169C>T;hgvs_aa=YP_009724389.1:p.Ser723Ser;hgvs_alias=YP_009724389.1:Ser543Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040455840455840456;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2455	2455	.	+	.	ID=ID_26;Name=L730L;alias=L550L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1714;ao=39;dp=1753;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2190T;aa_name=p.L730L;hgvs_nt=NC_045512.2:g.2190C>T;hgvs_aa=YP_009724389.1:p.Leu730Leu;hgvs_alias=YP_009724389.1:Leu550Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022247575584711923;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2483	2483	.	+	.	ID=ID_27;Name=I740V;alias=I560V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1737;ao=14;dp=1751;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A2218G;aa_name=p.I740V;hgvs_nt=NC_045512.2:g.2218A>G;hgvs_aa=YP_009724389.1:p.Ile740Val;hgvs_alias=YP_009724389.1:Ile560Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00799543118218161;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2536	2536	.	+	.	ID=ID_28;Name=V757V;alias=V577V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1746;ao=13;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2271T;aa_name=p.V757V;hgvs_nt=NC_045512.2:g.2271C>T;hgvs_aa=YP_009724389.1:p.Val757Val;hgvs_alias=YP_009724389.1:Val577Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007390562819783968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2607	2607	.	+	.	ID=ID_29;Name=T781I;alias=T601I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2342T;aa_name=p.T781I;hgvs_nt=NC_045512.2:g.2342C>T;hgvs_aa=YP_009724389.1:p.Thr781Ile;hgvs_alias=YP_009724389.1:Thr601Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2695	2695	.	+	.	ID=ID_30;Name=N810N;alias=N630N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=1691;ao=68;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2430T;aa_name=p.N810N;hgvs_nt=NC_045512.2:g.2430C>T;hgvs_aa=YP_009724389.1:p.Asn810Asn;hgvs_alias=YP_009724389.1:Asn630Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.038658328595793066;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2755	2755	.	+	.	ID=ID_31;Name=V830V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1749;ao=9;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G2490T;aa_name=p.V830V;hgvs_nt=NC_045512.2:g.2490G>T;hgvs_aa=YP_009724389.1:p.Val830Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005119453924914676;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2784	2784	.	+	.	ID=ID_32;Name=N840S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A2519G;aa_name=p.N840S;hgvs_nt=NC_045512.2:g.2519A>G;hgvs_aa=YP_009724389.1:p.Asn840Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2790	2790	.	+	.	ID=ID_33;Name=T842I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2525T;aa_name=p.T842I;hgvs_nt=NC_045512.2:g.2525C>T;hgvs_aa=YP_009724389.1:p.Thr842Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_34;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3234	3234	.	+	.	ID=ID_35;Name=Q990L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A2969T;aa_name=p.Q990L;hgvs_nt=NC_045512.2:g.2969A>T;hgvs_aa=YP_009724389.1:p.Gln990Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3351	3351	.	+	.	ID=ID_36;Name=S1029I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G3086T;aa_name=p.S1029I;hgvs_nt=NC_045512.2:g.3086G>T;hgvs_aa=YP_009724389.1:p.Ser1029Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3369	3369	.	+	.	ID=ID_37;Name=T1035I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1667;ao=92;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3104T;aa_name=p.T1035I;hgvs_nt=NC_045512.2:g.3104C>T;hgvs_aa=YP_009724389.1:p.Thr1035Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05230244457077885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3450	3450	.	+	.	ID=ID_38;Name=N1062S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A3185G;aa_name=p.N1062S;hgvs_nt=NC_045512.2:g.3185A>G;hgvs_aa=YP_009724389.1:p.Asn1062Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3630	3630	.	+	.	ID=ID_39;Name=V1122A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1710;ao=48;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T3365C;aa_name=p.V1122A;hgvs_nt=NC_045512.2:g.3365T>C;hgvs_aa=YP_009724389.1:p.Val1122Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.027303754266211604;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3692	3692	.	+	.	ID=ID_40;Name=V1143F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G3427T;aa_name=p.V1143F;hgvs_nt=NC_045512.2:g.3427G>T;hgvs_aa=YP_009724389.1:p.Val1143Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3893	3893	.	+	.	ID=ID_41;Name=E1210K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1671;ao=78;dp=1749;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G3628A;aa_name=p.E1210K;hgvs_nt=NC_045512.2:g.3628G>A;hgvs_aa=YP_009724389.1:p.Glu1210Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044596912521440824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3902	3902	.	+	.	ID=ID_42;Name=P1213S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1670;ao=78;dp=1748;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3637T;aa_name=p.P1213S;hgvs_nt=NC_045512.2:g.3637C>T;hgvs_aa=YP_009724389.1:p.Pro1213Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04462242562929062;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4002	4002	.	+	.	ID=ID_43;Name=T1246I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1700;ao=44;dp=1744;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3737T;aa_name=p.T1246I;hgvs_nt=NC_045512.2:g.3737C>T;hgvs_aa=YP_009724389.1:p.Thr1246Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02522935779816514;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4009	4009	.	+	.	ID=ID_44;Name=F1248F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1725;ao=18;dp=1743;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3744T;aa_name=p.F1248F;hgvs_nt=NC_045512.2:g.3744C>T;hgvs_aa=YP_009724389.1:p.Phe1248Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010327022375215147;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4090	4090	.	+	.	ID=ID_45;Name=D1275D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1685;ao=12;dp=1697;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3825T;aa_name=p.D1275D;hgvs_nt=NC_045512.2:g.3825C>T;hgvs_aa=YP_009724389.1:p.Asp1275Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007071302298173247;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	4184	4184	.	+	.	ID=ID_46;Name=G1307S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=10;dp=1699;sample_size=5;Reference_seq=GG;Variant_seq=AA;nt_name=g.G3919A;aa_name=p.G1307S;hgvs_nt=NC_045512.2:g.3919G>A;hgvs_aa=YP_009724389.1:p.Gly1307Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005885815185403178;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4184	4184	.	+	.	ID=ID_47;Name=G1307N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1689;dp=1699;sample_size=5;Reference_seq=GG;Variant_seq=AG;nt_name=g.GG3919_3920AA;aa_name=p.G1307N;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Gly1307Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9941141848145968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4300	4300	.	+	.	ID=ID_48;Name=V1345V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1666;ao=20;dp=1686;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G4035T;aa_name=p.V1345V;hgvs_nt=NC_045512.2:g.4035G>T;hgvs_aa=YP_009724389.1:p.Val1345Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011862396204033215;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4321	4321	.	+	.	ID=ID_49;Name=A1352A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1685;dp=1685;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C4056T;aa_name=p.A1352A;hgvs_nt=NC_045512.2:g.4056C>T;hgvs_aa=YP_009724389.1:p.Ala1352Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4331	4331	.	+	.	ID=ID_50;Name=L1356L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1669;ao=15;dp=1684;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C4066T;aa_name=p.L1356L;hgvs_nt=NC_045512.2:g.4066C>T;hgvs_aa=YP_009724389.1:p.Leu1356Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008907363420427554;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4613	4613	.	+	.	ID=ID_51;Name=L1450I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1307;ao=15;dp=1322;sample_size=5;Reference_seq=C;Variant_seq=A;nt_name=g.C4348A;aa_name=p.L1450I;hgvs_nt=NC_045512.2:g.4348C>A;hgvs_aa=YP_009724389.1:p.Leu1450Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0113464447806354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4752	4752	.	+	.	ID=ID_52;Name=T1496I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1726;ao=23;dp=1749;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C4487T;aa_name=p.T1496I;hgvs_nt=NC_045512.2:g.4487C>T;hgvs_aa=YP_009724389.1:p.Thr1496Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013150371640937679;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4891	4891	.	+	.	ID=ID_53;Name=T1542T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1741;ao=9;dp=1750;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C4626T;aa_name=p.T1542T;hgvs_nt=NC_045512.2:g.4626C>T;hgvs_aa=YP_009724389.1:p.Thr1542Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005142857142857143;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4975	4975	.	+	.	ID=ID_54;Name=V1570V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1688;ao=62;dp=1750;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G4710A;aa_name=p.V1570V;hgvs_nt=NC_045512.2:g.4710G>A;hgvs_aa=YP_009724389.1:p.Val1570Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03542857142857143;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5007	5007	.	+	.	ID=ID_55;Name=T1581M;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1739;ao=11;dp=1750;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C4742T;aa_name=p.T1581M;hgvs_nt=NC_045512.2:g.4742C>T;hgvs_aa=YP_009724389.1:p.Thr1581Met;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006285714285714286;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5332	5332	.	+	.	ID=ID_56;Name=K1689K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1739;ao=19;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G5067A;aa_name=p.K1689K;hgvs_nt=NC_045512.2:g.5067G>A;hgvs_aa=YP_009724389.1:p.Lys1689Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01080773606370876;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5392	5392	.	+	.	ID=ID_57;Name=N1709N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1747;ao=11;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C5127T;aa_name=p.N1709N;hgvs_nt=NC_045512.2:g.5127C>T;hgvs_aa=YP_009724389.1:p.Asn1709Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006257110352673493;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5512	5512	.	+	.	ID=ID_58;Name=N1749N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1739;ao=17;dp=1756;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C5247T;aa_name=p.N1749N;hgvs_nt=NC_045512.2:g.5247C>T;hgvs_aa=YP_009724389.1:p.Asn1749Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00968109339407745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5640	5640	.	+	.	ID=ID_59;Name=Q1792R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1739;ao=20;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A5375G;aa_name=p.Q1792R;hgvs_nt=NC_045512.2:g.5375A>G;hgvs_aa=YP_009724389.1:p.Gln1792Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01137009664582149;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5704	5704	.	+	.	ID=ID_60;Name=Q1813H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1722;ao=37;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G5439T;aa_name=p.Q1813H;hgvs_nt=NC_045512.2:g.5439G>T;hgvs_aa=YP_009724389.1:p.Gln1813His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021034678794769755;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6016	6016	.	+	.	ID=ID_61;Name=N1917N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1671;ao=88;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C5751T;aa_name=p.N1917N;hgvs_nt=NC_045512.2:g.5751C>T;hgvs_aa=YP_009724389.1:p.Asn1917Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.050028425241614556;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6196	6196	.	+	.	ID=ID_62;Name=P1977P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1743;ao=15;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C5931T;aa_name=p.P1977P;hgvs_nt=NC_045512.2:g.5931C>T;hgvs_aa=YP_009724389.1:p.Pro1977Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008532423208191127;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6198	6198	.	+	.	ID=ID_63;Name=S1978F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1707;ao=51;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C5933T;aa_name=p.S1978F;hgvs_nt=NC_045512.2:g.5933C>T;hgvs_aa=YP_009724389.1:p.Ser1978Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02901023890784983;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6336	6336	.	+	.	ID=ID_64;Name=S2024L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1676;ao=23;dp=1699;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C6071T;aa_name=p.S2024L;hgvs_nt=NC_045512.2:g.6071C>T;hgvs_aa=YP_009724389.1:p.Ser2024Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01353737492642731;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6342	6342	.	+	.	ID=ID_65;Name=D2026G;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1687;ao=12;dp=1699;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A6077G;aa_name=p.D2026G;hgvs_nt=NC_045512.2:g.6077A>G;hgvs_aa=YP_009724389.1:p.Asp2026Gly;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007062978222483814;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6500	6500	.	+	.	ID=ID_66;Name=P2079S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1672;ao=21;dp=1693;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C6235T;aa_name=p.P2079S;hgvs_nt=NC_045512.2:g.6235C>T;hgvs_aa=YP_009724389.1:p.Pro2079Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012404016538688719;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6537	6537	.	+	.	ID=ID_67;Name=G2091D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1733;ao=21;dp=1754;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G6272A;aa_name=p.G2091D;hgvs_nt=NC_045512.2:g.6272G>A;hgvs_aa=YP_009724389.1:p.Gly2091Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011972633979475485;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6706	6706	.	+	.	ID=ID_68;Name=N2147N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1727;ao=21;dp=1748;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C6441T;aa_name=p.N2147N;hgvs_nt=NC_045512.2:g.6441C>T;hgvs_aa=YP_009724389.1:p.Asn2147Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012013729977116704;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6720	6720	.	+	.	ID=ID_69;Name=T2152I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1733;ao=15;dp=1748;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C6455T;aa_name=p.T2152I;hgvs_nt=NC_045512.2:g.6455C>T;hgvs_aa=YP_009724389.1:p.Thr2152Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008581235697940504;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6739	6739	.	+	.	ID=ID_70;Name=T2158T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1719;ao=33;dp=1752;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A6474G;aa_name=p.T2158T;hgvs_nt=NC_045512.2:g.6474A>G;hgvs_aa=YP_009724389.1:p.Thr2158Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018835616438356163;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6740	6740	.	+	.	ID=ID_71;Name=R2159W;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1743;ao=9;dp=1752;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C6475T;aa_name=p.R2159W;hgvs_nt=NC_045512.2:g.6475C>T;hgvs_aa=YP_009724389.1:p.Arg2159Trp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005136986301369863;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6813	6813	.	+	.	ID=ID_72;Name=T2183I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C6548T;aa_name=p.T2183I;hgvs_nt=NC_045512.2:g.6548C>T;hgvs_aa=YP_009724389.1:p.Thr2183Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6930	6930	.	+	.	ID=ID_73;Name=N2222S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1730;ao=22;dp=1752;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A6665G;aa_name=p.N2222S;hgvs_nt=NC_045512.2:g.6665A>G;hgvs_aa=YP_009724389.1:p.Asn2222Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012557077625570776;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6973	6973	.	+	.	ID=ID_74;Name=L2236L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1738;ao=14;dp=1752;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A6708G;aa_name=p.L2236L;hgvs_nt=NC_045512.2:g.6708A>G;hgvs_aa=YP_009724389.1:p.Leu2236Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007990867579908675;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6993	6993	.	+	.	ID=ID_75;Name=L2243S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1741;ao=13;dp=1754;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T6728C;aa_name=p.L2243S;hgvs_nt=NC_045512.2:g.6728T>C;hgvs_aa=YP_009724389.1:p.Leu2243Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007411630558722919;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	7528	7528	.	+	.	ID=ID_76;Name=V2421V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C7263T;aa_name=p.V2421V;hgvs_nt=NC_045512.2:g.7263C>T;hgvs_aa=YP_009724389.1:p.Val2421Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	7749	7749	.	+	.	ID=ID_77;Name=T2495I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1726;ao=33;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C7484T;aa_name=p.T2495I;hgvs_nt=NC_045512.2:g.7484C>T;hgvs_aa=YP_009724389.1:p.Thr2495Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018760659465605456;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	7869	7869	.	+	.	ID=ID_78;Name=S2535L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1740;ao=18;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C7604T;aa_name=p.S2535L;hgvs_nt=NC_045512.2:g.7604C>T;hgvs_aa=YP_009724389.1:p.Ser2535Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010238907849829351;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	8895	8895	.	+	.	ID=ID_79;Name=T2877I;alias=T114I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1747;ao=11;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C8630T;aa_name=p.T2877I;hgvs_nt=NC_045512.2:g.8630C>T;hgvs_aa=YP_009724389.1:p.Thr2877Ile;hgvs_alias=YP_009724389.1:Thr114Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006257110352673493;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9344	9344	.	+	.	ID=ID_80;Name=L3027F;alias=L264F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=1756;dp=1756;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9079T;aa_name=p.L3027F;hgvs_nt=NC_045512.2:g.9079C>T;hgvs_aa=YP_009724389.1:p.Leu3027Phe;hgvs_alias=YP_009724389.1:Leu264Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9424	9424	.	+	.	ID=ID_81;Name=V3053V;alias=V290V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=1741;dp=1741;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A9159G;aa_name=p.V3053V;hgvs_nt=NC_045512.2:g.9159A>G;hgvs_aa=YP_009724389.1:p.Val3053Val;hgvs_alias=YP_009724389.1:Val290Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9430	9430	.	+	.	ID=ID_82;Name=I3055I;alias=I292I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1738;ao=19;dp=1757;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9165T;aa_name=p.I3055I;hgvs_nt=NC_045512.2:g.9165C>T;hgvs_aa=YP_009724389.1:p.Ile3055Ile;hgvs_alias=YP_009724389.1:Ile292Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010813887307911212;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9534	9534	.	+	.	ID=ID_83;Name=T3090I;alias=T327I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9269T;aa_name=p.T3090I;hgvs_nt=NC_045512.2:g.9269C>T;hgvs_aa=YP_009724389.1:p.Thr3090Ile;hgvs_alias=YP_009724389.1:Thr327Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9565	9565	.	+	.	ID=ID_84;Name=F3100F;alias=F337F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1738;ao=21;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9300T;aa_name=p.F3100F;hgvs_nt=NC_045512.2:g.9300C>T;hgvs_aa=YP_009724389.1:p.Phe3100Phe;hgvs_alias=YP_009724389.1:Phe337Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011938601478112564;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9643	9643	.	+	.	ID=ID_85;Name=I3126I;alias=I363I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1737;ao=22;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T9378C;aa_name=p.I3126I;hgvs_nt=NC_045512.2:g.9378T>C;hgvs_aa=YP_009724389.1:p.Ile3126Ile;hgvs_alias=YP_009724389.1:Ile363Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012507106310403639;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9693	9693	.	+	.	ID=ID_86;Name=A3143V;alias=A380V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=1749;ao=10;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9428T;aa_name=p.A3143V;hgvs_nt=NC_045512.2:g.9428C>T;hgvs_aa=YP_009724389.1:p.Ala3143Val;hgvs_alias=YP_009724389.1:Ala380Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005685048322910745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	10029	10029	.	+	.	ID=ID_87;Name=T3255I;alias=T492I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=16;dp=1759;sample_size=5;Reference_seq=CC;Variant_seq=TT;nt_name=g.C9764T;aa_name=p.T3255I;hgvs_nt=NC_045512.2:g.9764C>T;hgvs_aa=YP_009724389.1:p.Thr3255Ile;hgvs_alias=YP_009724389.1:Thr492Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009096077316657191;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10029	10029	.	+	.	ID=ID_87;Name=T3255I;alias=T492I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=1743;dp=1759;sample_size=5;Reference_seq=CC;Variant_seq=TC;nt_name=g.CC9764_9765TT;aa_name=p.T3255I;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Thr3255Ile;hgvs_alias=YP_009724389.1:Thr492Ile;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9909039226833428;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10183	10183	.	+	.	ID=ID_88;Name=I3306I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1655;ao=104;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9918T;aa_name=p.I3306I;hgvs_nt=NC_045512.2:g.9918C>T;hgvs_aa=YP_009724389.1:p.Ile3306Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.059124502558271744;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10198	10198	.	+	.	ID=ID_89;Name=D3311D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1;ao=1758;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C9933T;aa_name=p.D3311D;hgvs_nt=NC_045512.2:g.9933C>T;hgvs_aa=YP_009724389.1:p.Asp3311Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994314951677089;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10279	10279	.	+	.	ID=ID_90;Name=L3338L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1688;ao=71;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C10014T;aa_name=p.L3338L;hgvs_nt=NC_045512.2:g.10014C>T;hgvs_aa=YP_009724389.1:p.Leu3338Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04036384309266629;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10323	10323	.	+	.	ID=ID_91;Name=K3353R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1684;ao=75;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A10058G;aa_name=p.K3353R;hgvs_nt=NC_045512.2:g.10058A>G;hgvs_aa=YP_009724389.1:p.Lys3353Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04263786242183058;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	10447	10447	.	+	.	ID=ID_92;Name=P3395H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=GCC;Variant_seq=ACA;nt_name=g.GCC10182_10184ACA;aa_name=p.P3395H;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Pro3395His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10456	10456	.	+	.	ID=ID_93;Name=F3397F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1731;ao=26;dp=1757;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C10191T;aa_name=p.F3397F;hgvs_nt=NC_045512.2:g.10191C>T;hgvs_aa=YP_009724389.1:p.Phe3397Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014797951052931132;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10733	10733	.	+	.	ID=ID_94;Name=L3490F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1746;ao=13;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C10468T;aa_name=p.L3490F;hgvs_nt=NC_045512.2:g.10468C>T;hgvs_aa=YP_009724389.1:p.Leu3490Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007390562819783968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10829	10829	.	+	.	ID=ID_95;Name=I3522V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1740;ao=12;dp=1752;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A10564G;aa_name=p.I3522V;hgvs_nt=NC_045512.2:g.10564A>G;hgvs_aa=YP_009724389.1:p.Ile3522Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00684931506849315;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10886	10886	.	+	.	ID=ID_96;Name=G3541R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1698;ao=53;dp=1751;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G10621A;aa_name=p.G3541R;hgvs_nt=NC_045512.2:g.10621G>A;hgvs_aa=YP_009724389.1:p.Gly3541Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03026841804683038;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10889	10889	.	+	.	ID=ID_97;Name=R3542C;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=1728;ao=23;dp=1751;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C10624T;aa_name=p.R3542C;hgvs_nt=NC_045512.2:g.10624C>T;hgvs_aa=YP_009724389.1:p.Arg3542Cys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013135351227869789;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11020	11020	.	+	.	ID=ID_98;Name=L3585L;alias=L16L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1726;ao=23;dp=1749;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C10755T;aa_name=p.L3585L;hgvs_nt=NC_045512.2:g.10755C>T;hgvs_aa=YP_009724389.1:p.Leu3585Leu;hgvs_alias=YP_009724389.1:Leu16Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013150371640937679;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11077	11077	.	+	.	ID=ID_99;Name=F3604F;alias=F35F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1746;ao=13;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T10812C;aa_name=p.F3604F;hgvs_nt=NC_045512.2:g.10812T>C;hgvs_aa=YP_009724389.1:p.Phe3604Phe;hgvs_alias=YP_009724389.1:Phe35Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007390562819783968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11094	11094	.	+	.	ID=ID_100;Name=A3610V;alias=A41V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1719;ao=18;dp=1737;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C10829T;aa_name=p.A3610V;hgvs_nt=NC_045512.2:g.10829C>T;hgvs_aa=YP_009724389.1:p.Ala3610Val;hgvs_alias=YP_009724389.1:Ala41Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010362694300518135;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_101;Name=S3675del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=1739;dp=1739;sample_size=5;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=3676del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_101;Name=3676del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=1739;dp=1739;sample_size=5;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_101;Name=F3677del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=1739;dp=1739;sample_size=5;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=BF.7;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,3676del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11419	11419	.	+	.	ID=ID_102;Name=V3718V;alias=V149V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1728;ao=30;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T11154C;aa_name=p.V3718V;hgvs_nt=NC_045512.2:g.11154T>C;hgvs_aa=YP_009724389.1:p.Val3718Val;hgvs_alias=YP_009724389.1:Val149Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017064846416382253;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11572	11572	.	+	.	ID=ID_103;Name=F3769F;alias=F200F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1728;ao=31;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C11307T;aa_name=p.F3769F;hgvs_nt=NC_045512.2:g.11307C>T;hgvs_aa=YP_009724389.1:p.Phe3769Phe;hgvs_alias=YP_009724389.1:Phe200Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01762364980102331;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11750	11750	.	+	.	ID=ID_104;Name=L3829F;alias=L260F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1741;ao=17;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C11485T;aa_name=p.L3829F;hgvs_nt=NC_045512.2:g.11485C>T;hgvs_aa=YP_009724389.1:p.Leu3829Phe;hgvs_alias=YP_009724389.1:Leu260Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009670079635949944;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11774	11774	.	+	.	ID=ID_105;Name=A3837T;alias=A268T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1727;ao=32;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G11509A;aa_name=p.A3837T;hgvs_nt=NC_045512.2:g.11509G>A;hgvs_aa=YP_009724389.1:p.Ala3837Thr;hgvs_alias=YP_009724389.1:Ala268Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018192154633314382;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11804	11804	.	+	.	ID=ID_106;Name=V3847I;alias=V278I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1737;ao=22;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G11539A;aa_name=p.V3847I;hgvs_nt=NC_045512.2:g.11539G>A;hgvs_aa=YP_009724389.1:p.Val3847Ile;hgvs_alias=YP_009724389.1:Val278Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012507106310403639;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11995	11995	.	+	.	ID=ID_107;Name=K3910K;alias=K51K;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A11730G;aa_name=p.K3910K;hgvs_nt=NC_045512.2:g.11730A>G;hgvs_aa=YP_009724389.1:p.Lys3910Lys;hgvs_alias=YP_009724389.1:Lys51Lys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12049	12049	.	+	.	ID=ID_108;Name=N3928N;alias=N69N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=1721;ao=38;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C11784T;aa_name=p.N3928N;hgvs_nt=NC_045512.2:g.11784C>T;hgvs_aa=YP_009724389.1:p.Asn3928Asn;hgvs_alias=YP_009724389.1:Asn69Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02160318362706083;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12142	12142	.	+	.	ID=ID_109;Name=T3959T;alias=T17T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=A;nt_name=g.T11877A;aa_name=p.T3959T;hgvs_nt=NC_045512.2:g.11877T>A;hgvs_aa=YP_009724389.1:p.Thr3959Thr;hgvs_alias=YP_009724389.1:Thr17Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12160	12160	.	+	.	ID=ID_110;Name=E3965E;alias=E23E;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G11895A;aa_name=p.E3965E;hgvs_nt=NC_045512.2:g.11895G>A;hgvs_aa=YP_009724389.1:p.Glu3965Glu;hgvs_alias=YP_009724389.1:Glu23Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12283	12283	.	+	.	ID=ID_111;Name=D4006D;alias=D64D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=1654;ao=105;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T12018C;aa_name=p.D4006D;hgvs_nt=NC_045512.2:g.12018T>C;hgvs_aa=YP_009724389.1:p.Asp4006Asp;hgvs_alias=YP_009724389.1:Asp64Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05969300739056282;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12312	12312	.	+	.	ID=ID_112;Name=A4016V;alias=A74V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=1749;ao=10;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C12047T;aa_name=p.A4016V;hgvs_nt=NC_045512.2:g.12047C>T;hgvs_aa=YP_009724389.1:p.Ala4016Val;hgvs_alias=YP_009724389.1:Ala74Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005685048322910745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12473	12473	.	+	.	ID=ID_113;Name=L4070L;alias=L128L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C12208T;aa_name=p.L4070L;hgvs_nt=NC_045512.2:g.12208C>T;hgvs_aa=YP_009724389.1:p.Leu4070Leu;hgvs_alias=YP_009724389.1:Leu128Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12747	12747	.	+	.	ID=ID_114;Name=T4161I;alias=T21I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=1749;ao=10;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C12482T;aa_name=p.T4161I;hgvs_nt=NC_045512.2:g.12482C>T;hgvs_aa=YP_009724389.1:p.Thr4161Ile;hgvs_alias=YP_009724389.1:Thr21Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005685048322910745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12880	12880	.	+	.	ID=ID_115;Name=I4205I;alias=I65I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C12615T;aa_name=p.I4205I;hgvs_nt=NC_045512.2:g.12615C>T;hgvs_aa=YP_009724389.1:p.Ile4205Ile;hgvs_alias=YP_009724389.1:Ile65Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12970	12970	.	+	.	ID=ID_116;Name=N4235N;alias=N95N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C12705T;aa_name=p.N4235N;hgvs_nt=NC_045512.2:g.12705C>T;hgvs_aa=YP_009724389.1:p.Asn4235Asn;hgvs_alias=YP_009724389.1:Asn95Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13201	13201	.	+	.	ID=ID_117;Name=P4312P;alias=P59P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=1714;ao=45;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G12936T;aa_name=p.P4312P;hgvs_nt=NC_045512.2:g.12936G>T;hgvs_aa=YP_009724389.1:p.Pro4312Pro;hgvs_alias=YP_009724389.1:Pro59Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025582717453098352;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13258	13258	.	+	.	ID=ID_118;Name=R4331R;alias=R78R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=1722;ao=37;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T12993C;aa_name=p.R4331R;hgvs_nt=NC_045512.2:g.12993T>C;hgvs_aa=YP_009724389.1:p.Arg4331Arg;hgvs_alias=YP_009724389.1:Arg78Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021034678794769755;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13617	13617	.	+	.	ID=ID_119;Name=K4451K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1739;ao=20;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G13353A;aa_name=p.K4451K;hgvs_nt=NC_045512.2:g.13353G>A;hgvs_aa=YP_009724389.1:p.Lys4451Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01137009664582149;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13620	13620	.	+	.	ID=ID_120;Name=D4452D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1744;ao=14;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C13356T;aa_name=p.D4452D;hgvs_nt=NC_045512.2:g.13356C>T;hgvs_aa=YP_009724389.1:p.Asp4452Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007963594994311717;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13756	13756	.	+	.	ID=ID_121;Name=I4498V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1749;ao=10;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A13492G;aa_name=p.I4498V;hgvs_nt=NC_045512.2:g.13492A>G;hgvs_aa=YP_009724389.1:p.Ile4498Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005685048322910745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13821	13821	.	+	.	ID=ID_122;Name=L4519L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1745;ao=14;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C13557T;aa_name=p.L4519L;hgvs_nt=NC_045512.2:g.13557C>T;hgvs_aa=YP_009724389.1:p.Leu4519Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007959067652075043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14120	14120	.	+	.	ID=ID_123;Name=P4619L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1729;ao=30;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C13856T;aa_name=p.P4619L;hgvs_nt=NC_045512.2:g.13856C>T;hgvs_aa=YP_009724389.1:p.Pro4619Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017055144968732235;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14181	14181	.	+	.	ID=ID_124;Name=L4639F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1735;ao=24;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G13917C;aa_name=p.L4639F;hgvs_nt=NC_045512.2:g.13917G>C;hgvs_aa=YP_009724389.1:p.Leu4639Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013644115974985787;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_125;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14433	14433	.	+	.	ID=ID_126;Name=R4723R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1749;ao=10;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A14169G;aa_name=p.R4723R;hgvs_nt=NC_045512.2:g.14169A>G;hgvs_aa=YP_009724389.1:p.Arg4723Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005685048322910745;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14790	14790	.	+	.	ID=ID_127;Name=I4842I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1737;ao=10;dp=1747;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C14526T;aa_name=p.I4842I;hgvs_nt=NC_045512.2:g.14526C>T;hgvs_aa=YP_009724389.1:p.Ile4842Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005724098454493417;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14928	14928	.	+	.	ID=ID_128;Name=N4888N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1705;ao=41;dp=1746;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C14664T;aa_name=p.N4888N;hgvs_nt=NC_045512.2:g.14664C>T;hgvs_aa=YP_009724389.1:p.Asn4888Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.023482245131729668;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15654	15654	.	+	.	ID=ID_129;Name=D5130D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1745;ao=14;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C15390T;aa_name=p.D5130D;hgvs_nt=NC_045512.2:g.15390C>T;hgvs_aa=YP_009724389.1:p.Asp5130Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007959067652075043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15714	15714	.	+	.	ID=ID_130;Name=L5150L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C15450T;aa_name=p.L5150L;hgvs_nt=NC_045512.2:g.15450C>T;hgvs_aa=YP_009724389.1:p.Leu5150Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15763	15763	.	+	.	ID=ID_131;Name=L5167L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1741;ao=18;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C15499T;aa_name=p.L5167L;hgvs_nt=NC_045512.2:g.15499C>T;hgvs_aa=YP_009724389.1:p.Leu5167Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01023308698123934;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16056	16056	.	+	.	ID=ID_132;Name=H5264H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T15792C;aa_name=p.H5264H;hgvs_nt=NC_045512.2:g.15792T>C;hgvs_aa=YP_009724389.1:p.His5264His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16222	16222	.	+	.	ID=ID_133;Name=H5320Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C15958T;aa_name=p.H5320Y;hgvs_nt=NC_045512.2:g.15958C>T;hgvs_aa=YP_009724389.1:p.His5320Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16376	16376	.	+	.	ID=ID_134;Name=P5371L;alias=P47L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1739;ao=20;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C16112T;aa_name=p.P5371L;hgvs_nt=NC_045512.2:g.16112C>T;hgvs_aa=YP_009724389.1:p.Pro5371Leu;hgvs_alias=YP_009724389.1:Pro47Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01137009664582149;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16616	16616	.	+	.	ID=ID_135;Name=T5451I;alias=T127I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C16352T;aa_name=p.T5451I;hgvs_nt=NC_045512.2:g.16352C>T;hgvs_aa=YP_009724389.1:p.Thr5451Ile;hgvs_alias=YP_009724389.1:Thr127Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16650	16650	.	+	.	ID=ID_136;Name=L5462L;alias=L138L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1723;ao=36;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C16386T;aa_name=p.L5462L;hgvs_nt=NC_045512.2:g.16386C>T;hgvs_aa=YP_009724389.1:p.Leu5462Leu;hgvs_alias=YP_009724389.1:Leu138Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02046617396247868;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16726	16726	.	+	.	ID=ID_137;Name=H5488Y;alias=H164Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1744;ao=14;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C16462T;aa_name=p.H5488Y;hgvs_nt=NC_045512.2:g.16462C>T;hgvs_aa=YP_009724389.1:p.His5488Tyr;hgvs_alias=YP_009724389.1:His164Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007963594994311717;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16887	16887	.	+	.	ID=ID_138;Name=Y5541Y;alias=Y217Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1721;ao=36;dp=1757;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C16623T;aa_name=p.Y5541Y;hgvs_nt=NC_045512.2:g.16623C>T;hgvs_aa=YP_009724389.1:p.Tyr5541Tyr;hgvs_alias=YP_009724389.1:Tyr217Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020489470688673878;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16975	16975	.	+	.	ID=ID_139;Name=V5571F;alias=V247F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G16711T;aa_name=p.V5571F;hgvs_nt=NC_045512.2:g.16711G>T;hgvs_aa=YP_009724389.1:p.Val5571Phe;hgvs_alias=YP_009724389.1:Val247Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16995	16995	.	+	.	ID=ID_140;Name=Y5577Y;alias=Y253Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1735;ao=24;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C16731T;aa_name=p.Y5577Y;hgvs_nt=NC_045512.2:g.16731C>T;hgvs_aa=YP_009724389.1:p.Tyr5577Tyr;hgvs_alias=YP_009724389.1:Tyr253Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013644115974985787;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17122	17122	.	+	.	ID=ID_141;Name=A5620S;alias=A296S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1721;ao=36;dp=1757;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G16858T;aa_name=p.A5620S;hgvs_nt=NC_045512.2:g.16858G>T;hgvs_aa=YP_009724389.1:p.Ala5620Ser;hgvs_alias=YP_009724389.1:Ala296Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.020489470688673878;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17410	17410	.	+	.	ID=ID_142;Name=R5716C;alias=R392C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C17146T;aa_name=p.R5716C;hgvs_nt=NC_045512.2:g.17146C>T;hgvs_aa=YP_009724389.1:p.Arg5716Cys;hgvs_alias=YP_009724389.1:Arg392Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17586	17586	.	+	.	ID=ID_143;Name=D5774D;alias=D450D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1745;ao=14;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C17322T;aa_name=p.D5774D;hgvs_nt=NC_045512.2:g.17322C>T;hgvs_aa=YP_009724389.1:p.Asp5774Asp;hgvs_alias=YP_009724389.1:Asp450Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007959067652075043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17676	17676	.	+	.	ID=ID_144;Name=I5804I;alias=I480I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1656;ao=103;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C17412T;aa_name=p.I5804I;hgvs_nt=NC_045512.2:g.17412C>T;hgvs_aa=YP_009724389.1:p.Ile5804Ile;hgvs_alias=YP_009724389.1:Ile480Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05855599772598067;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17733	17733	.	+	.	ID=ID_145;Name=F5823F;alias=F499F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1728;ao=31;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C17469T;aa_name=p.F5823F;hgvs_nt=NC_045512.2:g.17469C>T;hgvs_aa=YP_009724389.1:p.Phe5823Phe;hgvs_alias=YP_009724389.1:Phe499Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01762364980102331;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17746	17746	.	+	.	ID=ID_146;Name=P5828S;alias=P504S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1720;ao=39;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C17482T;aa_name=p.P5828S;hgvs_nt=NC_045512.2:g.17482C>T;hgvs_aa=YP_009724389.1:p.Pro5828Ser;hgvs_alias=YP_009724389.1:Pro504Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022171688459351906;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17934	17934	.	+	.	ID=ID_147;Name=T5890T;alias=T566T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=1716;ao=43;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C17670T;aa_name=p.T5890T;hgvs_nt=NC_045512.2:g.17670C>T;hgvs_aa=YP_009724389.1:p.Thr5890Thr;hgvs_alias=YP_009724389.1:Thr566Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0244457077885162;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18163	18163	.	+	.	ID=ID_148;Name=I5967V;alias=I42V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=0;ao=1731;dp=1731;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A17899G;aa_name=p.I5967V;hgvs_nt=NC_045512.2:g.17899A>G;hgvs_aa=YP_009724389.1:p.Ile5967Val;hgvs_alias=YP_009724389.1:Ile42Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18318	18318	.	+	.	ID=ID_149;Name=G6018G;alias=G93G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1746;ao=13;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G18054T;aa_name=p.G6018G;hgvs_nt=NC_045512.2:g.18054G>T;hgvs_aa=YP_009724389.1:p.Gly6018Gly;hgvs_alias=YP_009724389.1:Gly93Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007390562819783968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18508	18508	.	+	.	ID=ID_150;Name=L6082F;alias=L157F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1743;ao=16;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C18244T;aa_name=p.L6082F;hgvs_nt=NC_045512.2:g.18244C>T;hgvs_aa=YP_009724389.1:p.Leu6082Phe;hgvs_alias=YP_009724389.1:Leu157Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009096077316657191;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18657	18657	.	+	.	ID=ID_151;Name=T6131T;alias=T206T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1667;ao=92;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C18393T;aa_name=p.T6131T;hgvs_nt=NC_045512.2:g.18393C>T;hgvs_aa=YP_009724389.1:p.Thr6131Thr;hgvs_alias=YP_009724389.1:Thr206Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05230244457077885;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18747	18747	.	+	.	ID=ID_152;Name=V6161V;alias=V236V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1688;ao=71;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C18483T;aa_name=p.V6161V;hgvs_nt=NC_045512.2:g.18483C>T;hgvs_aa=YP_009724389.1:p.Val6161Val;hgvs_alias=YP_009724389.1:Val236Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04036384309266629;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18900	18900	.	+	.	ID=ID_153;Name=V6212V;alias=V287V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T18636C;aa_name=p.V6212V;hgvs_nt=NC_045512.2:g.18636T>C;hgvs_aa=YP_009724389.1:p.Val6212Val;hgvs_alias=YP_009724389.1:Val287Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19009	19009	.	+	.	ID=ID_154;Name=D6249Y;alias=D324Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1744;ao=15;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G18745T;aa_name=p.D6249Y;hgvs_nt=NC_045512.2:g.18745G>T;hgvs_aa=YP_009724389.1:p.Asp6249Tyr;hgvs_alias=YP_009724389.1:Asp324Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008527572484366117;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19134	19134	.	+	.	ID=ID_155;Name=E6290E;alias=E365E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1720;ao=39;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A18870G;aa_name=p.E6290E;hgvs_nt=NC_045512.2:g.18870A>G;hgvs_aa=YP_009724389.1:p.Glu6290Glu;hgvs_alias=YP_009724389.1:Glu365Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022171688459351906;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19160	19160	.	+	.	ID=ID_156;Name=S6299F;alias=S374F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1743;ao=16;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C18896T;aa_name=p.S6299F;hgvs_nt=NC_045512.2:g.18896C>T;hgvs_aa=YP_009724389.1:p.Ser6299Phe;hgvs_alias=YP_009724389.1:Ser374Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009096077316657191;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19524	19524	.	+	.	ID=ID_157;Name=L6420L;alias=L495L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1730;ao=29;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C19260T;aa_name=p.L6420L;hgvs_nt=NC_045512.2:g.19260C>T;hgvs_aa=YP_009724389.1:p.Leu6420Leu;hgvs_alias=YP_009724389.1:Leu495Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01648664013644116;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19533	19533	.	+	.	ID=ID_158;Name=Y6423Y;alias=Y498Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1726;ao=33;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T19269C;aa_name=p.Y6423Y;hgvs_nt=NC_045512.2:g.19269T>C;hgvs_aa=YP_009724389.1:p.Tyr6423Tyr;hgvs_alias=YP_009724389.1:Tyr498Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018760659465605456;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19545	19545	.	+	.	ID=ID_159;Name=I6427I;alias=I502I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1747;ao=12;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C19281T;aa_name=p.I6427I;hgvs_nt=NC_045512.2:g.19281C>T;hgvs_aa=YP_009724389.1:p.Ile6427Ile;hgvs_alias=YP_009724389.1:Ile502Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006822057987492893;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19610	19610	.	+	.	ID=ID_160;Name=T6449I;alias=T524I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=1743;ao=16;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C19346T;aa_name=p.T6449I;hgvs_nt=NC_045512.2:g.19346C>T;hgvs_aa=YP_009724389.1:p.Thr6449Ile;hgvs_alias=YP_009724389.1:Thr524Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009096077316657191;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19955	19955	.	+	.	ID=ID_161;Name=T6564I;alias=T112I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=1743;dp=1743;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C19691T;aa_name=p.T6564I;hgvs_nt=NC_045512.2:g.19691C>T;hgvs_aa=YP_009724389.1:p.Thr6564Ile;hgvs_alias=YP_009724389.1:Thr112Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19983	19983	.	+	.	ID=ID_162;Name=V6573V;alias=V121V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1711;ao=36;dp=1747;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C19719T;aa_name=p.V6573V;hgvs_nt=NC_045512.2:g.19719C>T;hgvs_aa=YP_009724389.1:p.Val6573Val;hgvs_alias=YP_009724389.1:Val121Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0206067544361763;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20055	20055	.	+	.	ID=ID_163;Name=E6597E;alias=E145E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=1734;dp=1735;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A19791G;aa_name=p.E6597E;hgvs_nt=NC_045512.2:g.19791A>G;hgvs_aa=YP_009724389.1:p.Glu6597Glu;hgvs_alias=YP_009724389.1:Glu145Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994236311239193;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20131	20131	.	+	.	ID=ID_164;Name=A6623T;alias=A171T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1695;ao=64;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G19867A;aa_name=p.A6623T;hgvs_nt=NC_045512.2:g.19867G>A;hgvs_aa=YP_009724389.1:p.Ala6623Thr;hgvs_alias=YP_009724389.1:Ala171Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.036384309266628764;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20309	20309	.	+	.	ID=ID_165;Name=Y6682C;alias=Y230C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1745;ao=12;dp=1757;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A20045G;aa_name=p.Y6682C;hgvs_nt=NC_045512.2:g.20045A>G;hgvs_aa=YP_009724389.1:p.Tyr6682Cys;hgvs_alias=YP_009724389.1:Tyr230Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006829823562891292;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20376	20376	.	+	.	ID=ID_166;Name=I6704I;alias=I252I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1739;ao=18;dp=1757;sample_size=5;Reference_seq=T;Variant_seq=A;nt_name=g.T20112A;aa_name=p.I6704I;hgvs_nt=NC_045512.2:g.20112T>A;hgvs_aa=YP_009724389.1:p.Ile6704Ile;hgvs_alias=YP_009724389.1:Ile252Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010244735344336939;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20456	20456	.	+	.	ID=ID_167;Name=F6731S;alias=F279S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=1742;ao=15;dp=1757;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T20192C;aa_name=p.F6731S;hgvs_nt=NC_045512.2:g.20192T>C;hgvs_aa=YP_009724389.1:p.Phe6731Ser;hgvs_alias=YP_009724389.1:Phe279Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008537279453614115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20940	20940	.	+	.	ID=ID_168;Name=L6892L;alias=L94L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1737;ao=10;dp=1747;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G20676A;aa_name=p.L6892L;hgvs_nt=NC_045512.2:g.20676G>A;hgvs_aa=YP_009724389.1:p.Leu6892Leu;hgvs_alias=YP_009724389.1:Leu94Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005724098454493417;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21137	21137	.	+	.	ID=ID_169;Name=K6958R;alias=K160R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1737;ao=9;dp=1746;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A20873G;aa_name=p.K6958R;hgvs_nt=NC_045512.2:g.20873A>G;hgvs_aa=YP_009724389.1:p.Lys6958Arg;hgvs_alias=YP_009724389.1:Lys160Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005154639175257732;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21379	21379	.	+	.	ID=ID_170;Name=S7039P;alias=S241P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1732;ao=13;dp=1745;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T21115C;aa_name=p.S7039P;hgvs_nt=NC_045512.2:g.21115T>C;hgvs_aa=YP_009724389.1:p.Ser7039Pro;hgvs_alias=YP_009724389.1:Ser241Pro;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007449856733524355;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21516	21516	.	+	.	ID=ID_171;Name=N7084N;alias=N286N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=1721;ao=22;dp=1743;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C21252T;aa_name=p.N7084N;hgvs_nt=NC_045512.2:g.21252C>T;hgvs_aa=YP_009724389.1:p.Asn7084Asn;hgvs_alias=YP_009724389.1:Asn286Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012621916236374068;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_172;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1674;ao=78;dp=1752;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04452054794520548;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_172;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1674;ao=78;dp=1752;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04452054794520548;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_172;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1674;ao=78;dp=1752;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04452054794520548;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21617	21617	.	+	.	ID=ID_173;Name=T19I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=51;dp=1746;sample_size=5;Reference_seq=AC;Variant_seq=CT;nt_name=g.C56T;aa_name=p.T19I;hgvs_nt=NC_045512.2:g.56C>T;hgvs_aa=YP_009724390.1:p.Thr19Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029209621993127148;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21617	21617	.	+	.	ID=ID_174;Name=T19L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=51;dp=1746;sample_size=5;Reference_seq=AC;Variant_seq=GT;nt_name=g.AC55_56CT;aa_name=p.T19L;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Thr19Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029209621993127148;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21617	21617	.	+	.	ID=ID_175;Name=T19V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1644;dp=1746;sample_size=5;Reference_seq=AC;Variant_seq=AT;nt_name=g.AC55_56GT;aa_name=p.T19V;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Thr19Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9415807560137457;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21632	21632	.	+	.	ID=ID_176;Name=L24_A27delinsS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1753;dp=1753;sample_size=5;Reference_seq=TTACCCCCTG;Variant_seq=T;nt_name=g.71_79delTACCCCCTG;aa_name=p.L24_A27delinsS;hgvs_nt=NC_045512.2:g.71_79del;hgvs_aa=YP_009724390.1:p.Leu24_Ala27delinsSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21718	21718	.	+	.	ID=ID_177;Name=Q52Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1743;ao=11;dp=1754;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G156A;aa_name=p.Q52Q;hgvs_nt=NC_045512.2:g.156G>A;hgvs_aa=YP_009724390.1:p.Gln52Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006271379703534778;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_178;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	"ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1;citation=van Loon et al. (2021);comb_mutation=V70del,N501Y;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1;citation=Snell et al. (2021);comb_mutation=V70del,N501Y;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=V70del,N501Y;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=V70del,N501Y;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_180;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=V70del;function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	"ID=ID_181;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,V70del;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=V70del,N501Y;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=V70del,N501Y;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_180;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=V70del;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_180;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=V70del;function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_178;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_181;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,V70del;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_179;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=V70del,N501Y;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_181;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,V70del;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_178;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	"ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1;citation=van Loon et al. (2021);comb_mutation=H69del,N501Y;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1;citation=Snell et al. (2021);comb_mutation=H69del,N501Y;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=H69del,N501Y;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=H69del,N501Y;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_183;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=H69del;function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	"ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,H69del;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del,N501Y;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del,N501Y;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_183;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_183;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=H69del;function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_178;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,H69del;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_182;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del,N501Y;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1752;dp=1752;sample_size=5;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,H69del;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21777	21777	.	+	.	ID=ID_185;Name=G72V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1731;ao=21;dp=1754;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G215T;aa_name=p.G72V;hgvs_nt=NC_045512.2:g.215G>T;hgvs_aa=YP_009724390.1:p.Gly72Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011972633979475485;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21987	21987	.	+	.	ID=ID_186;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=28;dp=1743;sample_size=5;Reference_seq=GTGTTTA;Variant_seq=ATGT;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01606425702811245;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21987	21987	.	+	.	ID=ID_186;Name=G142D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=28;dp=1743;sample_size=5;Reference_seq=GTGTTTA;Variant_seq=ATGT;nt_name=g.G425A;aa_name=p.G142D;hgvs_nt=NC_045512.2:g.425G>A;hgvs_aa=YP_009724390.1:p.Gly142Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01606425702811245;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1;citation=Suryadevara et al. (2021);comb_mutation=;function_description=Selected twice in passage with mAb COV2-2489.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21987	21987	.	+	.	ID=ID_187;Name=G142_Y144delinsDV;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1715;dp=1743;sample_size=5;Reference_seq=GTGTTTA;Variant_seq=ATGTTTA;nt_name=g.GTGTTTA425_431ATGT;aa_name=p.G142_Y144delinsDV;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly142_Tyr144delinsAspVal;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9839357429718876;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22000	22000	.	+	.	ID=ID_188;Name=H146H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1733;ao=13;dp=1746;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C438T;aa_name=p.H146H;hgvs_nt=NC_045512.2:g.438C>T;hgvs_aa=YP_009724390.1:p.His146His;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0074455899198167235;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22200	22200	.	+	.	ID=ID_189;Name=V213G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1753;dp=1753;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T638G;aa_name=p.V213G;hgvs_nt=NC_045512.2:g.638T>G;hgvs_aa=YP_009724390.1:p.Val213Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22295	22295	.	+	.	ID=ID_190;Name=H245Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1718;ao=13;dp=1731;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C733T;aa_name=p.H245Y;hgvs_nt=NC_045512.2:g.733C>T;hgvs_aa=YP_009724390.1:p.His245Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007510109763142692;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22444	22444	.	+	.	ID=ID_191;Name=D294D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1741;ao=12;dp=1753;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C882T;aa_name=p.D294D;hgvs_nt=NC_045512.2:g.882C>T;hgvs_aa=YP_009724390.1:p.Asp294Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0068454078722190535;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22480	22480	.	+	.	ID=ID_192;Name=F306F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1720;ao=21;dp=1741;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C918T;aa_name=p.F306F;hgvs_nt=NC_045512.2:g.918C>T;hgvs_aa=YP_009724390.1:p.Phe306Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012062033314187249;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22578	22578	.	+	.	ID=ID_193;Name=G339D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1750;dp=1750;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G1016A;aa_name=p.G339D;hgvs_nt=NC_045512.2:g.1016G>A;hgvs_aa=YP_009724390.1:p.Gly339Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22578	22578	.	+	.	ID=ID_193;Name=G339D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1750;dp=1750;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G1016A;aa_name=p.G339D;hgvs_nt=NC_045512.2:g.1016G>A;hgvs_aa=YP_009724390.1:p.Gly339Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.3 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_194;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1750;dp=1750;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_194;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1750;dp=1750;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-022-05644-7;citation=Cao et al. (2022);comb_mutation=;function_description=Increase immune evasion.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_194;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1750;dp=1750;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22674	22674	.	+	.	ID=ID_195;Name=S371F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1743;dp=1743;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1112T;aa_name=p.S371F;hgvs_nt=NC_045512.2:g.1112C>T;hgvs_aa=YP_009724390.1:p.Ser371Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22679	22679	.	+	.	ID=ID_196;Name=S373P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1749;dp=1749;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T1117C;aa_name=p.S373P;hgvs_nt=NC_045512.2:g.1117T>C;hgvs_aa=YP_009724390.1:p.Ser373Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1128/mBio.02707-20;citation=Long et al. (2020);comb_mutation=;function_description=Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22686	22686	.	+	.	ID=ID_197;Name=ST375FA;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1746;dp=1746;sample_size=5;Reference_seq=CCA;Variant_seq=TCG;nt_name=g.CCA1124_1126TCG;aa_name=p.ST375FA;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr375PheAla;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22775	22775	.	+	.	ID=ID_198;Name=D405N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1749;dp=1749;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G1213A;aa_name=p.D405N;hgvs_nt=NC_045512.2:g.1213G>A;hgvs_aa=YP_009724390.1:p.Asp405Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22786	22786	.	+	.	ID=ID_199;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1748;dp=1748;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_201;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_201;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_202;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_203;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_201;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_201;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_202;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_200;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_201;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22855	22855	.	+	.	ID=ID_204;Name=G431G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1736;ao=22;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1293T;aa_name=p.G431G;hgvs_nt=NC_045512.2:g.1293C>T;hgvs_aa=YP_009724390.1:p.Gly431Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012514220705346985;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1;citation=Tandel et al. (2021);comb_mutation=;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_205;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_206;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_209;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=64;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GT;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03640500568828214;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_209;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_207;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_208;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1694;dp=1758;sample_size=5;Reference_seq=TG;Variant_seq=GG;nt_name=g.TG1355_1356GT;aa_name=p.L452R;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9635949943117179;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22992	22992	.	+	.	ID=ID_210;Name=ST477NK;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1754;dp=1758;sample_size=5;Reference_seq=GCAC;Variant_seq=ACAA;nt_name=g.GCAC1430_1433ACAA;aa_name=p.ST477NK;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr477AsnLys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9977246871444824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_211;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_211;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_211;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	"ID=ID_211;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_211;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_211;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_212;Name=F486V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1456G;aa_name=p.F486V;hgvs_nt=NC_045512.2:g.1456T>G;hgvs_aa=YP_009724390.1:p.Phe486Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 88% appearance in 2 passages against Regeneron monoclonal antibody RGN10933 @ 50ug/mL;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_212;Name=F486V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1456G;aa_name=p.F486V;hgvs_nt=NC_045512.2:g.1456T>G;hgvs_aa=YP_009724390.1:p.Phe486Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_212;Name=F486V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1456G;aa_name=p.F486V;hgvs_nt=NC_045512.2:g.1456T>G;hgvs_aa=YP_009724390.1:p.Phe486Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_212;Name=F486V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1456G;aa_name=p.F486V;hgvs_nt=NC_045512.2:g.1456T>G;hgvs_aa=YP_009724390.1:p.Phe486Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23018	23018	.	+	.	ID=ID_212;Name=F486V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=T;Variant_seq=G;nt_name=g.T1456G;aa_name=p.F486V;hgvs_nt=NC_045512.2:g.1456T>G;hgvs_aa=YP_009724390.1:p.Phe486Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.07 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1;citation=van Loon et al. (2021);comb_mutation=H69del,V70del;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1;citation=Snell et al. (2021);comb_mutation=H69del,V70del;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=H69del,V70del;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=H69del,V70del;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del,V70del;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_202;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del,V70del;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_203;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 g (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_202;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_209;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=L452R;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_214;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=H69del,V70del;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_213;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_215;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23075	23075	.	+	.	ID=ID_216;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://dx.doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23075	23075	.	+	.	ID=ID_216;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23202	23202	.	+	.	ID=ID_217;Name=T547K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1744;ao=11;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=A;nt_name=g.C1640A;aa_name=p.T547K;hgvs_nt=NC_045512.2:g.1640C>A;hgvs_aa=YP_009724390.1:p.Thr547Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006257110352673493;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23309	23309	.	+	.	ID=ID_218;Name=E583Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1707;ao=52;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G1747C;aa_name=p.E583Q;hgvs_nt=NC_045512.2:g.1747G>C;hgvs_aa=YP_009724390.1:p.Glu583Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029562251279135872;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H69del,V70del;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_201;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_172;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_208;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_201;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_202;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralnasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_208;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_208;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H69del,V70del;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_201;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_172;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_208;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_208;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_201;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_202;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (911 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationmean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_219;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_206;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H69del,V70del;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_215;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_201;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_172;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_208;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23422	23422	.	+	.	ID=ID_222;Name=V620V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1739;ao=20;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1860T;aa_name=p.V620V;hgvs_nt=NC_045512.2:g.1860C>T;hgvs_aa=YP_009724390.1:p.Val620Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01137009664582149;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_223;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_221;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_223;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_221;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_223;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_221;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23536	23536	.	+	.	ID=ID_224;Name=N658N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1736;ao=23;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C1974T;aa_name=p.N658N;hgvs_nt=NC_045512.2:g.1974C>T;hgvs_aa=YP_009724390.1:p.Asn658Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013075611142694713;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23557	23557	.	+	.	ID=ID_225;Name=P665P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1731;ao=28;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=A;nt_name=g.C1995A;aa_name=p.P665P;hgvs_nt=NC_045512.2:g.1995C>A;hgvs_aa=YP_009724390.1:p.Pro665Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015918135304150087;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	23599	23599	.	+	.	ID=ID_226;Name=NSP679KSH;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=12;dp=1738;sample_size=5;Reference_seq=TTCTCC;Variant_seq=GTCCCA;nt_name=g.TTCTCC2037_2042GTCCCA;aa_name=p.NSP679KSH;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.AsnSerPro679LysSerHis;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006904487917146145;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	23599	23599	.	+	.	ID=ID_226;Name=NSP679KSH;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1726;dp=1738;sample_size=5;Reference_seq=TTCTCC;Variant_seq=GTCTCA;nt_name=g.TTCTCC2037_2042GTCTCA;aa_name=p.NSP679KSH;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.AsnSerPro679LysSerHis;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9930955120828538;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23625	23625	.	+	.	ID=ID_227;Name=A688V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1700;ao=25;dp=1725;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2063T;aa_name=p.A688V;hgvs_nt=NC_045512.2:g.2063C>T;hgvs_aa=YP_009724390.1:p.Ala688Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014492753623188406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23634	23634	.	+	.	ID=ID_228;Name=S691F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1721;ao=11;dp=1732;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2072T;aa_name=p.S691F;hgvs_nt=NC_045512.2:g.2072C>T;hgvs_aa=YP_009724390.1:p.Ser691Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006351039260969977;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23638	23638	.	+	.	ID=ID_229;Name=I692I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1724;ao=9;dp=1733;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2076T;aa_name=p.I692I;hgvs_nt=NC_045512.2:g.2076C>T;hgvs_aa=YP_009724390.1:p.Ile692Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0051933064050779;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23802	23802	.	+	.	ID=ID_230;Name=T747I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1719;ao=12;dp=1731;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2240T;aa_name=p.T747I;hgvs_nt=NC_045512.2:g.2240C>T;hgvs_aa=YP_009724390.1:p.Thr747Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006932409012131715;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23854	23854	.	+	.	ID=ID_231;Name=N764K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1731;dp=1731;sample_size=5;Reference_seq=C;Variant_seq=A;nt_name=g.C2292A;aa_name=p.N764K;hgvs_nt=NC_045512.2:g.2292C>A;hgvs_aa=YP_009724390.1:p.Asn764Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23986	23986	.	+	.	ID=ID_232;Name=D808D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1722;ao=10;dp=1732;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T2424C;aa_name=p.D808D;hgvs_nt=NC_045512.2:g.2424T>C;hgvs_aa=YP_009724390.1:p.Asp808Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005773672055427252;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24210	24210	.	+	.	ID=ID_233;Name=T883I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1720;ao=13;dp=1733;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2648T;aa_name=p.T883I;hgvs_nt=NC_045512.2:g.2648C>T;hgvs_aa=YP_009724390.1:p.Thr883Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0075014425851125215;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24424	24424	.	+	.	ID=ID_234;Name=Q954H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1733;dp=1733;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A2862T;aa_name=p.Q954H;hgvs_nt=NC_045512.2:g.2862A>T;hgvs_aa=YP_009724390.1:p.Gln954His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24442	24442	.	+	.	ID=ID_235;Name=N960N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1723;ao=10;dp=1733;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C2880T;aa_name=p.N960N;hgvs_nt=NC_045512.2:g.2880C>T;hgvs_aa=YP_009724390.1:p.Asn960Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005770340450086555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24469	24469	.	+	.	ID=ID_236;Name=N969K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1734;dp=1734;sample_size=5;Reference_seq=T;Variant_seq=A;nt_name=g.T2907A;aa_name=p.N969K;hgvs_nt=NC_045512.2:g.2907T>A;hgvs_aa=YP_009724390.1:p.Asn969Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24499	24499	.	+	.	ID=ID_237;Name=D979D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1725;ao=10;dp=1735;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T2937C;aa_name=p.D979D;hgvs_nt=NC_045512.2:g.2937T>C;hgvs_aa=YP_009724390.1:p.Asp979Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005763688760806916;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24904	24904	.	+	.	ID=ID_238;Name=I1114I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1742;ao=17;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3342T;aa_name=p.I1114I;hgvs_nt=NC_045512.2:g.3342C>T;hgvs_aa=YP_009724390.1:p.Ile1114Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009664582148948267;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24919	24919	.	+	.	ID=ID_239;Name=N1119N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1745;ao=14;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3357T;aa_name=p.N1119N;hgvs_nt=NC_045512.2:g.3357C>T;hgvs_aa=YP_009724390.1:p.Asn1119Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007959067652075043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24933	24933	.	+	.	ID=ID_240;Name=G1124V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G3371T;aa_name=p.G1124V;hgvs_nt=NC_045512.2:g.3371G>T;hgvs_aa=YP_009724390.1:p.Gly1124Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25000	25000	.	+	.	ID=ID_241;Name=D1146D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C3438T;aa_name=p.D1146D;hgvs_nt=NC_045512.2:g.3438C>T;hgvs_aa=YP_009724390.1:p.Asp1146Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25302	25302	.	+	.	ID=ID_242;Name=C1247F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1735;ao=24;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G3740T;aa_name=p.C1247F;hgvs_nt=NC_045512.2:g.3740G>T;hgvs_aa=YP_009724390.1:p.Cys1247Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013644115974985787;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25526	25526	.	+	.	ID=ID_243;Name=W45L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1729;ao=29;dp=1758;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G134T;aa_name=p.W45L;hgvs_nt=NC_045512.2:g.134G>T;hgvs_aa=YP_009724391.1:p.Trp45Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016496018202502846;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25584	25584	.	+	.	ID=ID_244;Name=T64T;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1758;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C192T;aa_name=p.T64T;hgvs_nt=NC_045512.2:g.192C>T;hgvs_aa=YP_009724391.1:p.Thr64Thr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25613	25613	.	+	.	ID=ID_245;Name=S74F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1702;ao=56;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C221T;aa_name=p.S74F;hgvs_nt=NC_045512.2:g.221C>T;hgvs_aa=YP_009724391.1:p.Ser74Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03185437997724687;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25731	25731	.	+	.	ID=ID_246;Name=Y113Y;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1724;ao=33;dp=1757;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C339T;aa_name=p.Y113Y;hgvs_nt=NC_045512.2:g.339C>T;hgvs_aa=YP_009724391.1:p.Tyr113Tyr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018782014797951052;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25904	25904	.	+	.	ID=ID_247;Name=S171L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1748;ao=10;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C512T;aa_name=p.S171L;hgvs_nt=NC_045512.2:g.512C>T;hgvs_aa=YP_009724391.1:p.Ser171Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005688282138794084;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26060	26060	.	+	.	ID=ID_248;Name=T223I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C668T;aa_name=p.T223I;hgvs_nt=NC_045512.2:g.668C>T;hgvs_aa=YP_009724391.1:p.Thr223Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26101	26101	.	+	.	ID=ID_249;Name=V237F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1741;ao=18;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G709T;aa_name=p.V237F;hgvs_nt=NC_045512.2:g.709G>T;hgvs_aa=YP_009724391.1:p.Val237Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01023308698123934;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26110	26110	.	+	.	ID=ID_250;Name=P240S;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C718T;aa_name=p.P240S;hgvs_nt=NC_045512.2:g.718C>T;hgvs_aa=YP_009724391.1:p.Pro240Ser;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26185	26185	.	+	.	ID=ID_251;Name=D265N;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1750;ao=9;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G793A;aa_name=p.D265N;hgvs_nt=NC_045512.2:g.793G>A;hgvs_aa=YP_009724391.1:p.Asp265Asn;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00511654349061967;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	26270	26270	.	+	.	ID=ID_252;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=1759;sample_size=5;Reference_seq=CAG;Variant_seq=TAT;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008527572484366117;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26270	26270	.	+	.	ID=ID_253;Name=TG9IC;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1744;dp=1759;sample_size=5;Reference_seq=CAG;Variant_seq=TAG;nt_name=g.CAG26_28TAT;aa_name=p.TG9IC;hgvs_nt=n/a;hgvs_aa=YP_009724392.1:p.ThrGly9IleCys;hgvs_alias=n/a;vcf_gene=E;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9914724275156339;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26296	26296	.	+	.	ID=ID_254;Name=L18I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1681;ao=78;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=A;nt_name=g.C52A;aa_name=p.L18I;hgvs_nt=NC_045512.2:g.52C>A;hgvs_aa=YP_009724392.1:p.Leu18Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04434337691870381;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26408	26408	.	+	.	ID=ID_255;Name=S55F;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1743;ao=13;dp=1756;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C164T;aa_name=p.S55F;hgvs_nt=NC_045512.2:g.164C>T;hgvs_aa=YP_009724392.1:p.Ser55Phe;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007403189066059226;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26428	26428	.	+	.	ID=ID_256;Name=V62F;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1722;ao=34;dp=1756;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G184T;aa_name=p.V62F;hgvs_nt=NC_045512.2:g.184G>T;hgvs_aa=YP_009724392.1:p.Val62Phe;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0193621867881549;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26529	26529	.	+	.	ID=ID_257;Name=D3N;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1757;dp=1757;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G7A;aa_name=p.D3N;hgvs_nt=NC_045512.2:g.7G>A;hgvs_aa=YP_009724393.1:p.Asp3Asn;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26577	26577	.	+	.	ID=ID_258;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1756;dp=1756;sample_size=5;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26709	26709	.	+	.	ID=ID_259;Name=A63T;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G187A;aa_name=p.A63T;hgvs_nt=NC_045512.2:g.187G>A;hgvs_aa=YP_009724393.1:p.Ala63Thr;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26769	26769	.	+	.	ID=ID_260;Name=A83S;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1748;ao=11;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G247T;aa_name=p.A83S;hgvs_nt=NC_045512.2:g.247G>T;hgvs_aa=YP_009724393.1:p.Ala83Ser;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0062535531552018195;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26801	26801	.	+	.	ID=ID_261;Name=L93L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1737;ao=22;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C279T;aa_name=p.L93L;hgvs_nt=NC_045512.2:g.279C>T;hgvs_aa=YP_009724393.1:p.Leu93Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012507106310403639;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26907	26907	.	+	.	ID=ID_262;Name=L129L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1665;ao=94;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C385T;aa_name=p.L129L;hgvs_nt=NC_045512.2:g.385C>T;hgvs_aa=YP_009724393.1:p.Leu129Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.053439454235361;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27038	27038	.	+	.	ID=ID_263;Name=T172T;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1742;dp=1742;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A516G;aa_name=p.T172T;hgvs_nt=NC_045512.2:g.516A>G;hgvs_aa=YP_009724393.1:p.Thr172Thr;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27396	27396	.	+	.	ID=ID_264;Name=M1?;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=(ORF7a|GU280_gp07|1|1.00);mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1733;ao=9;dp=1742;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G3T;aa_name=p.M1?;hgvs_nt=NC_045512.2:g.3G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005166475315729047;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	27398	27398	.	+	.	ID=ID_265;Name=I3V;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1586;ao=9;dp=1741;sample_size=5;Reference_seq=AAA;Variant_seq=CAG;nt_name=g.A7G;aa_name=p.I3V;hgvs_nt=NC_045512.2:g.7A>G;hgvs_aa=YP_009724395.1:p.Ile3Val;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005169442848937392;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27398	27398	.	+	.	ID=ID_266;Name=KI2TV;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1586;ao=9;dp=1741;sample_size=5;Reference_seq=AAA;Variant_seq=AGA;nt_name=g.AAA5_7CAG;aa_name=p.KI2TV;hgvs_nt=n/a;hgvs_aa=YP_009724395.1:p.LysIle2ThrVal;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005169442848937392;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27398	27398	.	+	.	ID=ID_267;Name=K2K;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1586;ao=137;dp=1741;sample_size=5;Reference_seq=AAA;Variant_seq=AAG;nt_name=g.A6G;aa_name=p.K2K;hgvs_nt=NC_045512.2:g.6A>G;hgvs_aa=YP_009724395.1:p.Lys2Lys;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07869040781160253;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27425	27425	.	+	.	ID=ID_268;Name=T11I;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1726;ao=16;dp=1742;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C32T;aa_name=p.T11I;hgvs_nt=NC_045512.2:g.32C>T;hgvs_aa=YP_009724395.1:p.Thr11Ile;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009184845005740528;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27450	27450	.	+	.	ID=ID_269;Name=H19Q;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1594;ao=145;dp=1739;sample_size=5;Reference_seq=C;Variant_seq=A;nt_name=g.C57A;aa_name=p.H19Q;hgvs_nt=NC_045512.2:g.57C>A;hgvs_aa=YP_009724395.1:p.His19Gln;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08338125359401956;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27532	27532	.	+	.	ID=ID_270;Name=H47Y;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1729;ao=24;dp=1754;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C139T;aa_name=p.H47Y;hgvs_nt=NC_045512.2:g.139C>T;hgvs_aa=YP_009724395.1:p.His47Tyr;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013683010262257697;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27612	27612	.	+	.	ID=ID_271;Name=H73H;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1646;ao=65;dp=1711;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C219T;aa_name=p.H73H;hgvs_nt=NC_045512.2:g.219C>T;hgvs_aa=YP_009724395.1:p.His73His;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03798947983635301;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27621	27621	.	+	.	ID=ID_272;Name=Q76Q;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1710;ao=10;dp=1720;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G228A;aa_name=p.Q76Q;hgvs_nt=NC_045512.2:g.228G>A;hgvs_aa=YP_009724395.1:p.Gln76Gln;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005813953488372093;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27634	27634	.	+	.	ID=ID_273;Name=S81P;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1741;ao=13;dp=1754;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T241C;aa_name=p.S81P;hgvs_nt=NC_045512.2:g.241T>C;hgvs_aa=YP_009724395.1:p.Ser81Pro;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007411630558722919;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27807	27807	.	+	.	ID=ID_274;Name=L18L;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1757;dp=1757;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18L;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009725318.1:p.Leu18Leu;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27889	27889	.	+	.	ID=ID_275;Name=g.C-5T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=10;ao=1713;dp=1723;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C-5T;aa_name=;hgvs_nt=NC_045512.2:g.5C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9941961694718514;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27921	27921	.	+	.	ID=ID_276;Name=I10F;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1646;ao=89;dp=1735;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A28T;aa_name=p.I10F;hgvs_nt=NC_045512.2:g.28A>T;hgvs_aa=YP_009724396.1:p.Ile10Phe;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051296829971181554;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28053	28053	.	+	.	ID=ID_277;Name=S54P;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1632;ao=88;dp=1720;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T160C;aa_name=p.S54P;hgvs_nt=NC_045512.2:g.160T>C;hgvs_aa=YP_009724396.1:p.Ser54Pro;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05116279069767442;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28076	28076	.	+	.	ID=ID_278;Name=C61C;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1658;ao=62;dp=1721;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C183T;aa_name=p.C61C;hgvs_nt=NC_045512.2:g.183C>T;hgvs_aa=YP_009724396.1:p.Cys61Cys;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03602556653108658;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28077	28077	.	+	.	ID=ID_279;Name=V62L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1690;ao=31;dp=1721;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G184T;aa_name=p.V62L;hgvs_nt=NC_045512.2:g.184G>T;hgvs_aa=YP_009724396.1:p.Val62Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01801278326554329;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	28089	28089	.	+	.	ID=ID_280;Name=G66_K68delinsE;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1706;ao=12;dp=1721;sample_size=5;Reference_seq=GGTTCTA;Variant_seq=G;nt_name=g.197_202delGTTCTA;aa_name=p.G66_K68delinsE;hgvs_nt=NC_045512.2:g.197_202del;hgvs_aa=YP_009724396.1:p.Gly66_Lys68delinsGlu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006972690296339338;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28109	28109	.	+	.	ID=ID_281;Name=Q72H;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1680;ao=42;dp=1722;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G216T;aa_name=p.Q72H;hgvs_nt=NC_045512.2:g.216G>T;hgvs_aa=YP_009724396.1:p.Gln72His;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024390243902439025;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28146	28146	.	+	.	ID=ID_282;Name=P85S;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1691;ao=33;dp=1724;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C253T;aa_name=p.P85S;hgvs_nt=NC_045512.2:g.253C>T;hgvs_aa=YP_009724396.1:p.Pro85Ser;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0191415313225058;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	28149	28149	.	+	.	ID=ID_283;Name=T87_I88del;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1708;ao=13;dp=1722;sample_size=5;Reference_seq=TTTACAA;Variant_seq=T;nt_name=g.260_265delCAATTA;aa_name=p.T87_I88del;hgvs_nt=NC_045512.2:g.260_265del;hgvs_aa=YP_009724396.1:p.Thr87_Ile88del;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007549361207897794;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28175	28175	.	+	.	ID=ID_284;Name=K94K;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1674;ao=51;dp=1725;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A282G;aa_name=p.K94K;hgvs_nt=NC_045512.2:g.282A>G;hgvs_aa=YP_009724396.1:p.Lys94Lys;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029565217391304348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28233	28233	.	+	.	ID=ID_285;Name=V114L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1711;ao=21;dp=1732;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G340C;aa_name=p.V114L;hgvs_nt=NC_045512.2:g.340G>C;hgvs_aa=YP_009724396.1:p.Val114Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01212471131639723;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28271	28271	.	+	.	ID=ID_286;Name=g.A-3T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1737;dp=1737;sample_size=5;Reference_seq=A;Variant_seq=T;nt_name=g.A-3T;aa_name=;hgvs_nt=NC_045512.2:g.3A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28311	28311	.	+	.	ID=ID_287;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1744;dp=1744;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28311	28311	.	+	.	ID=ID_287;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1744;dp=1744;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28330	28330	.	+	.	ID=ID_288;Name=G19G;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=1744;dp=1745;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A57G;aa_name=p.G19G;hgvs_nt=NC_045512.2:g.57A>G;hgvs_aa=YP_009724397.2:p.Gly19Gly;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994269340974212;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	28361	28361	.	+	.	ID=ID_289;Name=G30_S33delinsF;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1739;dp=1741;sample_size=5;Reference_seq=GGAGAACGCAG;Variant_seq=TT;nt_name=g.GGAGAACGCAG88_98TT;aa_name=p.G30_S33delinsF;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.Gly30_Ser33delinsPhe;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9988512349224583;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28541	28541	.	+	.	ID=ID_290;Name=A90S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1658;ao=90;dp=1748;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G268T;aa_name=p.A90S;hgvs_nt=NC_045512.2:g.268G>T;hgvs_aa=YP_009724397.2:p.Ala90Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05148741418764302;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28606	28606	.	+	.	ID=ID_291;Name=Y111Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1735;ao=15;dp=1750;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C333T;aa_name=p.Y111Y;hgvs_nt=NC_045512.2:g.333C>T;hgvs_aa=YP_009724397.2:p.Tyr111Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008571428571428572;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28657	28657	.	+	.	ID=ID_292;Name=D128D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1741;ao=10;dp=1751;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C384T;aa_name=p.D128D;hgvs_nt=NC_045512.2:g.384C>T;hgvs_aa=YP_009724397.2:p.Asp128Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0057110222729868645;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28809	28809	.	+	.	ID=ID_293;Name=G179D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1697;ao=62;dp=1759;sample_size=5;Reference_seq=G;Variant_seq=A;nt_name=g.G536A;aa_name=p.G179D;hgvs_nt=NC_045512.2:g.536G>A;hgvs_aa=YP_009724397.2:p.Gly179Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03524729960204662;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28849	28849	.	+	.	ID=ID_294;Name=N192N;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1701;ao=58;dp=1759;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C576T;aa_name=p.N192N;hgvs_nt=NC_045512.2:g.576C>T;hgvs_aa=YP_009724397.2:p.Asn192Asn;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03297328027288232;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	mnp	28881	28881	.	+	.	ID=ID_295;Name=RG203KR;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1759;dp=1759;sample_size=5;Reference_seq=GGG;Variant_seq=AAC;nt_name=g.GGG608_610AAC;aa_name=p.RG203KR;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.ArgGly203LysArg;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28905	28905	.	+	.	ID=ID_296;Name=A211V;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1731;ao=24;dp=1755;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C632T;aa_name=p.A211V;hgvs_nt=NC_045512.2:g.632C>T;hgvs_aa=YP_009724397.2:p.Ala211Val;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013675213675213675;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28969	28969	.	+	.	ID=ID_297;Name=S232S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1730;ao=28;dp=1758;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C696T;aa_name=p.S232S;hgvs_nt=NC_045512.2:g.696C>T;hgvs_aa=YP_009724397.2:p.Ser232Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015927189988623434;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29000	29000	.	+	.	ID=ID_298;Name=G243C;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1679;ao=78;dp=1757;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G727T;aa_name=p.G243C;hgvs_nt=NC_045512.2:g.727G>T;hgvs_aa=YP_009724397.2:p.Gly243Cys;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0443938531587934;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29272	29272	.	+	.	ID=ID_299;Name=Y333Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1732;ao=25;dp=1757;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C999T;aa_name=p.Y333Y;hgvs_nt=NC_045512.2:g.999C>T;hgvs_aa=YP_009724397.2:p.Tyr333Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014228799089356859;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29403	29403	.	+	.	ID=ID_300;Name=D377G;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1737;ao=19;dp=1756;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A1130G;aa_name=p.D377G;hgvs_nt=NC_045512.2:g.1130A>G;hgvs_aa=YP_009724397.2:p.Asp377Gly;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01082004555808656;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29510	29510	.	+	.	ID=ID_301;Name=S413R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1755;dp=1755;sample_size=5;Reference_seq=A;Variant_seq=C;nt_name=g.A1237C;aa_name=p.S413R;hgvs_nt=NC_045512.2:g.1237A>C;hgvs_aa=YP_009724397.2:p.Ser413Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29542	29542	.	+	.	ID=ID_302;Name=g.A-16G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1676;ao=78;dp=1754;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A-16G;aa_name=;hgvs_nt=NC_045512.2:g.16A>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04446978335233751;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29627	29627	.	+	.	ID=ID_303;Name=R24C;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1739;ao=15;dp=1754;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C70T;aa_name=p.R24C;hgvs_nt=NC_045512.2:g.70C>T;hgvs_aa=YP_009725255.1:p.Arg24Cys;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00855188141391106;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29645	29645	.	+	.	ID=ID_304;Name=V30L;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1718;ao=23;dp=1741;sample_size=5;Reference_seq=G;Variant_seq=C;nt_name=g.G88C;aa_name=p.V30L;hgvs_nt=NC_045512.2:g.88G>C;hgvs_aa=YP_009725255.1:p.Val30Leu;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013210798391728892;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29667	29667	.	+	.	ID=ID_305;Name=L37P;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1625;ao=9;dp=1634;sample_size=5;Reference_seq=T;Variant_seq=C;nt_name=g.T110C;aa_name=p.L37P;hgvs_nt=NC_045512.2:g.110T>C;hgvs_aa=YP_009725255.1:p.Leu37Pro;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0055079559363525096;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29700	29700	.	+	.	ID=ID_306;Name=g.A29700G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1483;ao=29;dp=1512;sample_size=5;Reference_seq=A;Variant_seq=G;nt_name=g.A29700G;aa_name=;hgvs_nt=NC_045512.2:g.29700A>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01917989417989418;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29708	29708	.	+	.	ID=ID_307;Name=g.C29708T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1470;ao=14;dp=1484;sample_size=5;Reference_seq=C;Variant_seq=T;nt_name=g.C29708T;aa_name=;hgvs_nt=NC_045512.2:g.29708C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009433962264150943;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	29734	29734	.	+	.	ID=ID_308;Name=g.GAGGCCACGCGGAGTACGATCGAGTGTAC29734TAT;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=4;dp=185;sample_size=5;Reference_seq=GAGGCCACGCGGAGTACGATCGAGTGTAC;Variant_seq=TAT;nt_name=g.GAGGCCACGCGGAGTACGATCGAGTGTAC29734TAT;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021621621621621623;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	29734	29734	.	+	.	ID=ID_309;Name=g.GAGGCCACGCGGAGTACGATCGAGTGTAC29734TAC;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=180;dp=185;sample_size=5;Reference_seq=GAGGCCACGCGGAGTACGATCGAGTGTAC;Variant_seq=TAC;nt_name=g.GAGGCCACGCGGAGTACGATCGAGTGTAC29734TAC;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29764	29764	.	+	.	ID=ID_310;Name=g.G29764T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=184;ao=1;dp=185;sample_size=5;Reference_seq=G;Variant_seq=T;nt_name=g.G29764T;aa_name=;hgvs_nt=NC_045512.2:g.29764G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=BF.7;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
